Botox for chronic migraine billing: J0585 and 64615.
Two codes carry this entire service — 64615 for the chemodenervation procedure and J0585 for the drug — and both are billed on a logic that trips up practices that treat Botox like any other injection: 64615 is reported once per session regardless of how many of the 31 PREEMPT sites were injected, while J0585 tracks the exact unit count administered from a single-use vial. Add a medical-necessity threshold Medicare and commercial payers enforce as a hard gate, a bundling trap with a lookalike code, and a Botulinum Toxin LCD landscape that turned over twice in the last few months, and this is one of neurology's highest-denial-risk services when the billing logic isn't followed exactly.
Key takeaways
- 64615 is billed once per session, never per injection site. The code covers bilateral chemodenervation of the facial, trigeminal, cervical spinal, and accessory nerve muscle groups as a single unit of service — billing it multiple times to reflect the 31 PREEMPT sites is a coding error, not a documentation nuance.
- J0585 units have to match the operative note's site-by-site dosing, not just a total. A note that states "155 units given" without a per-muscle breakdown doesn't support the code the way an itemized PREEMPT table does, and payers increasingly audit against the named protocol.
- The Botulinum Toxin LCD landscape turned over twice since late 2025. Three MACs retired their LCDs 02/21/2026, four replacements went live 02/22/2026, WPS followed 04/02/2026, and the attached billing-and-coding articles were revised again as recently as 04/09/2026 — a scrubber rule citing last year's article number is citing a document that no longer applies.
- 64612 and 64615 cover overlapping muscle groups. Billing both same-day without two genuinely separate, separately-targeted indications is unbundling, not two distinct services, regardless of how the encounter is documented.
64615 and J0585: how the pairing actually works
64615 reports chemodenervation of the muscles innervated by the facial, trigeminal, cervical spinal, and accessory nerves, bilaterally, for chronic migraine — a paraphrase, not the AMA's official long descriptor. It is a single unit of service per session. The PREEMPT injection paradigm treats up to 31 sites across seven muscle groups in one sitting, but the code doesn't scale with site count; report it once, regardless of whether the physician used the fixed 31-site pattern or added follow-the-pain sites. Billing 64615 multiple times, or billing it per muscle group, is a fabricated unit count the payer's system will either deny outright or, worse, pay incorrectly and flag on a later audit.
J0585 reports onabotulinumtoxinA, per unit — this is the drug charge, separate from the injection procedure, and its units track the actual dose delivered, not a flat number. Because onabotulinumtoxinA ships in single-use vials (commonly reconstituted from 100-unit or 200-unit vials) that rarely divide evenly into a 155- or 195-unit treatment dose, most sessions leave some reconstituted drug unused. Single-dose container drugs generally require the claim line to carry either modifier JW (units of drug discarded and not administered, with the discarded amount documented) or modifier JZ (attestation that zero drug was discarded) — a J0585 line missing both is a common, entirely avoidable cause of an otherwise-correct claim rejecting. ⚠️ This build could not confirm your specific MAC's current JW/JZ enforcement posture against a primary CMS source; verify the requirement is active for your jurisdiction before submitting, since it has moved from optional to mandatory in phases for single-dose drugs generally.
PREEMPT injection-site and dosage documentation
The fixed-site, fixed-dose PREEMPT paradigm is the de facto documentation standard payers check claims against: 5 units per site, 31 sites, 155 units minimum, across seven muscle groups. The operative note has to reflect the sites and per-site dosage actually used — a total unit count alone doesn't support the code on audit.
| Muscle group | Sites | Units |
|---|---|---|
| Corrugator | 2 (1 each side) | 10 |
| Procerus | 1 (midline) | 5 |
| Frontalis | 4 (2 each side) | 20 |
| Temporalis | 8 (4 each side) | 40 |
| Occipitalis | 6 (3 each side) | 30 |
| Cervical paraspinal | 4 (2 each side) | 20 |
| Trapezius | 6 (3 each side) | 30 |
| Fixed-site total | 31 | 155 |
The "follow-the-pain" option adds up to 40 more units — distributed at the treating physician's discretion across the temporalis, occipitalis, and trapezius — for patients whose pain concentrates in those regions, bringing the maximum session dose to 195 units. The note needs to name which additional sites received the extra dose and how many units each one got; "additional units given for pain" without a site breakdown is the specific gap that turns an otherwise-clean chart into a documentation denial.
Build the PREEMPT site table directly into the EHR's injection template rather than relying on a free-text note. A structured template that forces a units-per-site entry for all 31 (or more) sites makes the total self-verifying — if the sum doesn't match the J0585 units billed, the chart flags it before the claim goes out, not after a payer catches it.
The chronic-migraine diagnostic threshold and the headache diary
Medical necessity for Botox turns on a specific, documented frequency threshold: 15 or more headache days per month, with at least 8 of those meeting migraine criteria, sustained for 3 consecutive months. A headache diary, app-based tracker, or equivalent calendar log showing dated entries — not a physician's summary statement like "frequent migraines" — is what most payers actually want to see in the chart and the prior-auth packet.
Diagnosis coding should track the clinical picture as specifically as the chart supports. G43.7xx (chronic migraine without aura) and G43.Exx (chronic migraine with aura) each split by intractability and by presence of status migrainosus — we verified the full set live against the FY2026 ICD-10-CM code set.
| Presentation | Not intractable | Intractable |
|---|---|---|
| Without aura, without status migrainosus | G43.709 | G43.719 |
| Without aura, with status migrainosus | G43.701 | G43.711 |
| With aura, without status migrainosus | G43.E09 | G43.E19 |
| With aura, with status migrainosus | G43.E01 | G43.E11 |
The intractable designation is worth getting right, not just technically correct: a genuinely treatment-refractory patient coded as "not intractable" understates the clinical picture the prior-auth reviewer is evaluating, and it's a more common error than the reverse. If the chart documents failed preventive trials and ongoing disabling frequency despite them, the intractable code (G43.711, G43.719, G43.E11, or G43.E19) is usually the one the record actually supports.
Prior authorization: what payers actually check
Approval turnaround depends on submitting a complete packet the first time, not a resubmission after a request for more information. Payers consistently check the same six elements before approving an initial or renewal Botox authorization:
- 1Dated headache diary or calendar showing the 15/8/3-month threshold, not a narrative summary.
- 2Documented trial and failure (or contraindication/intolerance) of at least two oral preventive drug classes — commonly a beta-blocker, an anticonvulsant such as topiramate, and a tricyclic; some payers require three. This is where the FDA-label-versus-payer-policy trap covered in our neurology pillar guide shows up most often — check the specific payer's step-therapy list rather than assuming the label's requirements apply.
- 3Correct, specific ICD-10 code reflecting intractability and status migrainosus status where the chart supports it, not a default unspecified selection.
- 4A validated headache-impact score — MIDAS or HIT-6 — where the payer's policy asks for one; omitting it is a frequent, avoidable cause of an initial pend.
- 5Confirmation of the retreatment interval. Botox for chronic migraine follows a roughly 12-week cycle; a reauthorization request submitted before that interval has elapsed reads as premature to most payers' utilization review.
- 6Prescriber specialty. Some commercial and Medicare Advantage plans restrict initial Botox authorization to a neurologist or headache specialist — confirm the plan's requirement before scheduling if the ordering physician isn't one.
The 64612 unbundling trap
64612 reports chemodenervation of facial-nerve-innervated muscles, unilateral — the code used for blepharospasm and hemifacial spasm — and its target muscles overlap substantially with the muscle groups 64615 covers for chronic migraine. Billing both on the same date is unbundling, not two distinct services, unless the record independently supports two genuinely separate indications treated at non-overlapping injection sites.
- Confirm which single indication is driving today's visit before selecting a code, rather than defaulting to whichever pays more.
- If a patient genuinely carries both diagnoses, schedule the two treatments on separate calendar days where clinically feasible, so the encounters are unambiguously distinct.
- Get the payer's coverage position on same-day billing of both codes in writing before you rely on it, not after the claim denies.
- Don't bill 64612 same-day as 64615 because the exam also notes occasional eyelid twitching — incidental findings aren't a second billable indication.
- Don't assume a favorable NCCI modifier indicator makes routine same-day billing safe; it means an override is possible with documentation, not default practice.
- Don't code an encounter under 64612 to route around a chronic-migraine prior-auth delay — that's miscoding to the diagnosis, not billing to what was actually done.
Current Botulinum Toxin LCD coverage by MAC
"The LCD says" is meaningless here without naming the MAC and confirming the version, because this coverage family turned over twice in the last several months. We confirmed the following directly against the CMS Coverage Database.
| MAC | Current LCD | Effective | Current article | Article effective |
|---|---|---|---|---|
| Palmetto GBA | L39836 | 02/22/2026 | A59714 | 04/09/2026 |
| CGS Administrators | L39857 | 02/22/2026 | A59726 | 04/09/2026 |
| Noridian Healthcare Solutions | L35172 / L35170 | 02/22/2026 | A57186 / A57185 | 04/09/2026 |
| Wellpoint Federal | L39832 | 02/22/2026 | A59707 | 04/09/2026 |
| WPS Insurance Corporation | L39909 | 04/02/2026 | A59809 | 04/09/2026 |
| First Coast Service Options | L33274 | 11/09/2025 | A57715 | 11/09/2025 |
| Novitas Solutions | L38809 | 11/09/2025 | A58423 | 11/09/2025 |
| National Government Services | Prior LCD L33646 and article A52848 retired 02/21/2026. ⚠️ No current replacement document was located under this title in this build — confirm directly with NGS if this is your jurisdiction. | |||
Two things worth noting beyond the retirement dates themselves. First, the LCDs that went effective 02/22/2026 had their attached billing-and-coding articles revised again as recently as 04/09/2026 — the coverage policy's effective date and the article's most recent revision date aren't the same thing, and the article is usually where the covered-diagnosis list and documentation requirements actually live. Second, WPS Insurance Corporation's replacement LCD (L39909) went effective over five weeks after the other MACs' replacements, meaning a WPS-jurisdiction claim submitted in early March 2026 may have hit a genuine coverage gap between the retired L34635 and the new L39909 — worth checking if you have any denied claims from that window. ⚠️ This build confirmed the document IDs and effective/retirement dates above directly against the CMS Coverage Database; the covered-diagnosis lists and specific documentation requirements inside each article were not independently re-verified here (CMS's own article pages blocked automated retrieval during this build), so pull the specific article text for your MAC before finalizing an order-set rule against it.
Botox claims denying or underpaying?
We'll audit a sample of your recent Botox chronic migraine claims against your MAC's current LCD, name the specific documentation gaps, and show what's actually recoverable.
Frequently asked questions
How many units of J0585 do we bill for a single chronic migraine treatment session?
Bill J0585 in units matching the actual dose administered, not the vial size. Standard PREEMPT dosing is 155 units — 31 sites, 5 units each, across seven muscle groups — with an optional follow-the-pain increment of up to 40 more units in the temporalis, occipitalis, and trapezius for patients with predominant pain there, for a maximum of 195 units. Report 64615 once per session regardless of site count; it is not a per-site or per-unit code. Single-dose container drugs like onabotulinumtoxinA generally require either the JW modifier (documenting discarded units) or JZ modifier (attesting zero waste) on the claim line — ⚠️ this build could not confirm your specific MAC's current JW/JZ enforcement date against a primary CMS source, so confirm it before submitting, because a line missing both is a common cause of an otherwise-correct J0585 claim rejecting.
Can 64615 and 64612 ever be billed together, or is it always unbundling?
Rarely, and only where the record shows two genuinely separate indications with separate injection targets — for example, a patient treated for chronic migraine who also carries a documented hemifacial spasm diagnosis, injected in non-overlapping muscle territory. Even then, get the payer's specific coverage position in writing before billing both, because the muscle groups the two codes cover overlap substantially and most payers treat same-day billing of both as unbundling regardless of what the NCCI modifier indicator technically allows. ⚠️ The current modifier indicator for this specific pair could not be confirmed against CMS's primary NCCI file in this build — look it up in the CMS NCCI PTP Edits Lookup Tool before relying on an override modifier.
Which Botulinum Toxin LCD governs our claim now that the February 2026 retirement wave has taken effect?
It depends on your MAC, and the citation has changed twice in the last few months. WPS's, National Government Services', and CGS's prior LCDs (L34635, L33646, L33949) all retired 02/21/2026; Palmetto GBA (L39836), CGS (L39857), Noridian (L35172 and L35170), and Wellpoint Federal (L39832) published new versions effective 02/22/2026, and WPS's replacement (L39909) followed later, effective 04/02/2026 — all confirmed live in the CMS Coverage Database. The billing-and-coding articles attached to those LCDs were then revised again, most recently effective 04/09/2026, so pull whichever article version is currently posted for your MAC rather than one a scrubber rule cited last winter. ⚠️ National Government Services' specific replacement LCD could not be located under this title in this build — confirm directly with NGS if that's your jurisdiction.
Verify before billing. CPT is a registered trademark of the American Medical Association; codes here are paraphrased, not reproduced from the CPT Professional edition. CPT, HCPCS and ICD-10 codes, coverage policy, and bundling edits change, including annual code-set updates. This page reflects standard industry practice and is provided for general education — it is not a substitute for your own compliance review, your current payer contracts, or the current-year code sets. Confirm requirements against your specific payer mix before submitting claims.